A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Active:	Yes
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT06312137
Trial Phases:	Phase III	Protocol IDs:	2870-019 (primary) NCI-2024-05549 2023-508012-35 jRCT2021240020 MK-2870-019 U1111-1297-4260
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp and Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06312137

Summary

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery
is effective in treating NSCLC for participants not achieving pathological complete
response. The primary hypothesis of this study is sacituzumab tirumotecan plus
pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free
survival (DFS) as assessed by blinded independent central review (BICR).

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

Doctors:

Barry D. Luskey MD

Lester E. Robertson MD, FACP

Mark A. Taylor MD

Grant C. Lewis MD

Stephen Andrew White M.D.

Michael Chahin DO

Leonard Henry MD, FACS

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.